Quality Control of Biologics - Ensuring Safety Through Aggregation Analysis

Quality control of biologics requires stringent monitoring of product quality attributes, including protein aggregates – a key biologics quality attribute. Regulatory standards demand high purity at manufacture and throughout shelf life.
Aggregation analysis is pivotal, as protein aggregates can compromise safety and efficacy. Thus, controlling aggregation is essential to ensure biologics remain safe and effective.

Why Protein Aggregation Is a Critical Quality Attribute in Biologics?

Protein aggregation in biologics is recognized as a critical quality attribute. Even small amounts of aggregates can impact a product’s safety and effectiveness. Aggregates are essentially product-related impurities that may trigger immune reactions in patients. For example, aggregated proteins, particularly subvisible and insoluble species, have been linked to unwanted immunogenicity. This can lead to adverse effects like allergic responses or the formation of anti-drug antibodies.¹

Such immune responses can reduce a biologic’s efficacy and pose serious safety risks. Moreover, protein aggregates can reduce the amount of active drug (monomer) available, directly diminishing potency. Because of these risks, manufacturers and regulators treat aggregation as a high-risk attribute. It must be tightly controlled throughout product development, manufacturing, and quality control of biologics, including routine quality control testing.

Mechanisms and Risk Factors Driving Aggregation in Biologic Products

Proteins are inherently prone to aggregation under certain conditions. The mechanisms driving aggregation often involve partial unfolding or structural perturbations that expose hydrophobic patches, causing proteins to self-associate. In some cases, covalent changes like disulfide bond scrambling or oxidation can also lead to aggregate formation. Multiple factors in a biologic’s lifecycle can trigger these changes. Extremes of pH, high ionic strength (depending on the protein and formulation), or elevated temperature can increase protein aggregation. Mechanical stresses encountered during manufacturing of biologics and handling – such as pumping, filtration, agitation, or fill–finish operations have a similar effect. High protein concentration is another risk factor. Biologics formulated at hundreds of milligrams per milliliter face increased molecular interactions that promote aggregation^2,3, which is a key consideration in the quality control of biologics.

Aggregation driver	Physicochemical mechanism	Structural impact on protein	Typical manufacturing or handling source	Aggregation type promoted	Reversibility	Relevance for QC and risk mitigation
pH shifts	Changes in pH alter protein charge distribution and electrostatic repulsion. This destabilizes native folding and increases intermolecular attraction.	Partial unfolding exposes hydrophobic regions and reactive amino acids. Electrostatic screening promotes self-association.	Low pH viral inactivation, buffer exchange, formulation errors, storage outside specification.	Soluble oligomers and irreversible aggregates depending on exposure duration.	Often irreversible after prolonged exposure; transient pH excursions may still induce lasting effects.	Critical during downstream processing and formulation. Requires tight pH control and monitoring, as transient pH shifts can result in irreversible aggregation.
Temperature stress	Elevated temperatures increase molecular mobility and weaken non-covalent stabilizing interactions.	Thermal unfolding leads to exposure of hydrophobic cores and aggregation-prone motifs.	Cell culture excursions, purification steps, accelerated stability studies, improper cold chain handling.	Irreversible high molecular weight aggregates and particulates.	Generally irreversible once denaturation occurs.	Key factor in biologics stability and aggregation risk. Stress testing supports shelf-life assignment and release specifications.
Agitation and shear stress	Mechanical forces disrupt protein structure and enhance collisions between molecules.	Local unfolding at air–liquid or solid–liquid interfaces. Increased surface adsorption and desorption cycles.	Pumping, mixing, filtration, filling operations, shipping and transportation.	Both soluble aggregates and subvisible particles.	Mostly irreversible due to interfacial denaturation.	Highly relevant for GMP quality control biologics. Drives container and process design decisions.
Freeze–thaw cycles	Ice formation concentrates proteins and solutes in unfrozen regions. pH and ionic strength shift locally.	Cryo-concentration causes unfolding and increased protein–protein interactions.	Bulk drug substance storage, repeated sampling, improper handling during logistics.	Soluble oligomers and visible or subvisible aggregates.	Often partially reversible initially, irreversible after repeated cycles.	Controlled freeze–thaw studies are required for biologics safety testing and comparability assessments.
High protein concentration	Reduced intermolecular distance increases collision frequency and attractive interactions.	Native structure remains intact initially but transient interactions become stabilized.	High-dose formulations, ultrafiltration and diafiltration steps.	Reversible and irreversible self-association.	Often reversible at early stages, irreversible at high stress.	Major concern for modern high-concentration biologics. Drives need for advanced and orthogonal analytical methods for aggregation analysis.
Oxidative stress	Reactive oxygen species modify sensitive amino acids such as methionine or tryptophan.	Chemical modification destabilizes tertiary structure and promotes aggregation.	Exposure to light, metal ions, excipient impurities, oxygen ingress.	Irreversible covalent aggregates.	Irreversible.	Often detected during stability studies. Requires orthogonal aggregation testing to assess impact on product quality..
Ionic strength changes	Changes in salt concentration alter electrostatic interactions between molecules.	Depending on the protein and formulation, altered electrostatic balance may promote or reduce self-association.	Buffer preparation errors, process scale-up variability.	Soluble oligomers.	Often reversible depending on magnitude and duration.	Relevant during formulation development and interpretation of SEC aggregation analysis .
Surface interactions	Adsorption to glass, stainless steel, or polymer surfaces destabilizes proteins.	Surface-induced unfolding promotes aggregation upon desorption.	Containers, tubing, filters, syringes.	Subvisible and visible particles.	Irreversible.	Critical for container closure system selection and release testing decisions.

Tab. 1. Aggregation Risk Factors Across Biologics Manufacturing and Operations.

Some biologics are more aggregation-prone than others due to less stable folding or reactive amino acid residues. As a result of these varied mechanisms, different types of aggregates can form. They range from small soluble oligomers to large insoluble particles. Importantly, larger and irreversible aggregates are generally of greatest concern, whereas small reversible oligomers may be less problematic. Understanding the conditions and risk factors that drive aggregation is critical for designing robust manufacturing processes and selecting appropriate analytical controls.⁴

Analytical Techniques Used for Aggregation Analysis in Quality Control

A variety of analytical methods for aggregation analysis are employed to detect and quantify protein aggregates. These tests are part of GMP quality control of biologics. Size-exclusion chromatography (SEC) is a primary technique for aggregation analysis in biologics quality control, used to separate monomer from higher molecular weight species. SEC aggregation analysis is widely used to determine the percentage of aggregates in a sample. It is a standard part of biologics release testing.⁵

However, SEC has limitations. It may suffer from column interactions or may not accurately resolve very large aggregates. To ensure reliable results, regulatory agencies recommend orthogonal analytical methods to complement SEC. In fact, quantitative or semi-quantitative measurement of aggregate levels is required by regulators for therapeutic protein where aggregation represents a critical quality attribute.

Orthogonal techniques for aggregation analysis include sedimentation velocity analytical ultracentrifugation (AUC) and field-flow fractionation (for example, asymmetric-flow field-flow fractionation). These methods separate aggregates by different physical principles and can detect aggregates that SEC might miss and are commonly applied during protein characterization as part of broader product characterization, comparability assessments, and root-cause investigations to detect aggregate populations that may not be resolved by SEC. Light scattering techniques are also widely used. For instance, SEC coupled with multi-angle light scattering (SEC-MALS) can determine the molecular weight of eluting aggregates. Dynamic light scattering (DLS) can rapidly assess the presence of larger aggregates in a sample. Other assays like nanoparticle tracking analysis or micro-flow imaging target subvisible particulate aggregates.⁶

Quality control labs often use a combination of these analytical methods for aggregation testing. This approach provides a comprehensive profile of a biologic’s aggregation state. All methods used for biologics aggregation analysis in GMP environment must be appropriately validated to ensure accuracy and reproducibility. This analytical vigilance enables manufacturers to detect any aberrant aggregation early and take corrective actions.

Aggregation Analysis Across the Biologics Manufacturing Lifecycle

Aggregation control and analysis are integrated throughout the biologic product’s manufacturing lifecycle. Protein aggregation can originate at any stage, from cell culture and purification to final formulation and storage. For example, a protein may start to aggregate during cell culture if it is produced at high levels. Suboptimal folding conditions in the bioreactor can also trigger aggregation. Downstream processing steps like purification can also influence aggregation. For example, low pH viral inactivation or exposure to air-water interfaces during filtration might induce some proteins to aggregate. At the formulation development stage, significant effort is devoted to creating a stable formulation.⁷

The goal is to minimize aggregation throughout the product’s shelf life. Excipients such as sugars, amino acids, or surfactants are often added to stabilize the protein. They help prevent aggregation during stresses like freezing, thawing, or agitation. During fill-finish, manufacturers use gentle handling and optimized containers to avoid inducing aggregates. Aggregation analysis is also a crucial part of quality control of biologics, including biologics release testing for each batch. Final product lots are tested to ensure aggregate levels are within specifications before approval for patient use. Stability and aggregation of biologics are closely linked. Any increase in aggregation under recommended storage conditions must remain within acceptable limits. This requirement ensures the biologic remains safe and effective until expiry.⁸

If a manufacturing process is modified or a facility is changed, comparability studies include aggregation analysis. This testing confirms the new process does not elevate aggregate levels. In summary, from early development through production and storage, aggregation testing of biologics is a continuous thread. It detects issues early and ensures that control strategies effectively maintain low aggregate levels across the product lifecycle.

Regulatory Expectations for Aggregation Control in Biologics Quality Control

Regulatory authorities place significant emphasis on controlling protein aggregates in biologic products. No single regulatory guideline is dedicated solely to aggregates. However, general quality guidance treats aggregates as impurities that require appropriate characterization and control.^9,10

Consequently, biologics license applications are expected to include specifications for aggregate content. Quantitative or semi-quantitative aggregate analysis is a requirement in quality control testing where aggregation represents a critical quality attribute. Regulators expect manufacturers to establish acceptable aggregate limits based on clinical safety data and manufacturing capability. By the time of product approval, a company should provide a science-based justification for its aggregate limits. This justification is supported by analytical data and often clinical experience. For example, a monoclonal antibody that triggers immune reactions above a certain aggregate level will have a stricter aggregate limit. The manufacturer sets its specification below that threshold. A margin of safety is included in this limit. This expectation stems from the concern that undiscovered aggregates could pose immunogenicity risks.

Orthogonal methods are therefore viewed favorably in regulatory filings. The use of orthogonal analytical methods to support aggregation assessment is therefore viewed favorably in regulatory submissions. All aggregate testing must be performed in compliance with GMP requirements as part of the quality control of biologics, and analytical methods must be validated for their intended purpose. Overall, the regulatory requirements for aggregation analysis drive manufacturers to maintain tight control over this critical quality attribute. This focus applies throughout a biologics process development and commercial manufacturing.

Interpreting Aggregation Data to Ensure Biologics Safety and Consistency

The final step in aggregation quality control is interpreting the data to make informed decisions about product safety and consistency. Quality control of biologics specialists routinely review aggregate measurement results for each manufactured batch and across stability timepoints to confirm that results remain within established specifications and are consistent with trends. If a batch’s aggregate level is out of specification or unusually high, it signals a potential problem. For instance, the cause could be a process deviation or a formulation issue. In such cases, the batch may be withheld from release. An upward drift in aggregate levels over successive lots prompts a root cause investigation. The same applies to any unexpected increase during stability testing. In practice, a risk-based approach is used.¹¹

Not all aggregates are equally harmful. Understanding the nature, size, and reversibility of aggregates helps assess their potential risk. During development and throughout a product’s lifecycle, manufacturers may evaluate correlations between aggregate levels, product stability profiles, and available clinical or immunogenicity data to establish and refine acceptable aggregate limits.

This scientific understanding, combined with robust analytical monitoring and trend analysis, forms the foundation of an effective aggregation control strategy. In conclusion, careful interpretation of aggregation data helps ensure that biologic products released to the market consistently meet approved quality standards, supporting patient safety and reliable therapeutic performance.

Conclusion

Ensuring biologics safety requires more than measuring aggregate levels alone; it demands a deep understanding of aggregation mechanisms and their clinical relevance. Aggregation analysis provides critical insight into protein stability, process robustness, and product consistency when interpreted through a risk-based framework. By correlating aggregation data with manufacturing conditions, formulation design, and immunogenicity outcomes, quality teams can distinguish acceptable variability from true safety concerns. Regulatory expectations further reinforce the need for quantitative or otherwise appropriately justified, science-based aggregation control strategies.

This integrated scientific approach strengthens aggregation control strategies, supports regulatory compliance, and ultimately ensures that biologic therapies delivered to patients remain safe, effective, and consistent throughout their entire shelf life.

FAQ

Protein aggregation is a critical quality attribute because aggregates can trigger immunogenic responses, reduce therapeutic efficacy, and compromise patient safety. Even low levels of aggregates may lead to adverse immune reactions or loss of potency, making tight control essential throughout the product lifecycle.

Size-exclusion chromatography coupled with UV detection (SEC-HPLC-UV) is the primary method used to quantify aggregates in biologics. SEC separates aggregates from monomers based on hydrodynamic size under non-denaturing conditions, enabling reliable measurement of dimers and higher-order species. In more advanced or confirmatory studies, SEC-HPLC is often complemented with orthogonal techniques such as size-exclusion chromatography coupled with multi-angle light scattering (SEC-MALS) or analytical ultracentrifugation (AUC) to better characterize aggregate size and molecular weight.

Regulators treat protein aggregates as product-related impurities that must be appropriately characterized and controlled. They expect manufacturers to define science-based aggregate limits, apply validated analytical methods, and use orthogonal approaches to ensure aggregation remains within acceptable, clinically justified ranges under GMP conditions.

Prepared by:

Amanda Jabłońska

Physicochemical and Biological Testing Division Manager

a.jablonska@mabion.eu

Jakub Knurek

Marketing Specialist

j.knurek@mabion.eu

References

Lundahl MLE, Fogli S, Colavita PE, Scanlan EM. Aggregation of protein therapeutics enhances their immunogenicity: causes and mitigation strategies. RSC Chem Biol. 2021 May 4;2(4):1004-1020.
Pham NB, Meng WS. Protein aggregation and immunogenicity of biotherapeutics. Int J Pharm. 2020; 585: 119523.
Rojekar S, Gholap AD, Jadhav K, Shevalkar G, Sugandhi VV, Pai R, Parikh K, Prajapati MK, Desai N, Vora LK, Ingle RG, Paudel KR. Exploring Protein Aggregation in Biological Products: From Mechanistic Understanding to Practical Solutions. AAPS PharmSciTech. 2025; 26(6): 189.
Pang KT, Yang YS, Zhang W, Ho YS, Sormanni P, Michaels TCT, Walsh I, Chia S. Understanding and controlling the molecular mechanisms of protein aggregation in mAb therapeutics. Biotechnol Adv. 2023; 67: 108192.
Toboła P, Knurek J. SEC-HPLC-UV as a Critical Quality Attribute Tool for Monitoring Protein Aggregation in Biologic Manufacturing. Mabion Science Hub. 2026.
Bou-Assaf GM, Budyak IL, Brenowitz M, Day ES, Hayes D, Hill J, Majumdar R, Ringhieri P, Schuck P, Lin JC. Best Practices for Aggregate Quantitation of Antibody Therapeutics by Sedimentation Velocity Analytical Ultracentrifugation. J Pharm Sci. 2022; 111(7): 2121-2133.
Zhang C, Bye JW, Lui LH, Zhang H, Hales J, Brocchini S, Curtis RA, Dalby PA. Enhanced Thermal Stability and Reduced Aggregation in an Antibody Fab Fragment at Elevated Concentrations. Mol Pharm. 2023; 20(5): 2650-2661.
Knez B, Erzin L, Kos Ž, Kuzman D, Ravnik M. Prediction of aggregation in monoclonal antibodies from molecular surface curvature. Sci Rep. 2025; 15(1): 28266.
ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. 1999.
ICH Q5C Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products. 1996.
Hendrickson BA, Agarwal A, Bennett D, Kübler J, McShea C, Tremmel L. Value and Implementation of the Aggregate Safety Assessment Plan. Pharmaceut Med. 2023; 37(3): 171-181.